Back to Results

Nasus Pharma Ltd (NSRX)

Featured in Overvalued Stocks

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal treatments for emergency medical situations. The company’s pipeline is centered on Powder-Based Intranasal (PBI) products designed for acute conditions and certain public health threats. Its reported product candidates include NS002, an intranasal epinephrine program intended to support treatment in severe allergic reaction emergencies, and NS001, an intranasal naloxone powder nasal spray being developed for opioid overdose treatment. Founded in 2019, Nasus Pharma is based in Tel Aviv-Yafo, Israel, and its common stock is listed on the NYSE under the symbol NSRX.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-NSRX
$2.37
-21.7% Downside
Overvalued
$19.67
549.1% Upside
Bargain
Weak
—
—
—
0.0%
September 2, 2026
-6.1x
12.8x
—
35.25 M
31.316 M
0.3%
41.5%
-10.6
—
85.0%
Send a message
Valuation • Fair Value

Nasus Pharma Ltd (NYSE-NSRX) Fair Value by Valuation Model

Compare the primary fair value estimate for Nasus Pharma Ltd (NYSE-NSRX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$2.37

Estimated downside of 21.7% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$2.37

Comparable-company valuation reference.

Analyst Price Target

$19.67

Analysts imply upside of 549.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Nasus Pharma Ltd (NYSE-NSRX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Nasus Pharma Ltd (NYSE-NSRX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Nasus Pharma Ltd (NYSE-NSRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nasus Pharma Ltd (NYSE-NSRX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-10.6

Lower score that deserves closer risk review.

FCF / Net Income

85.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nasus Pharma Ltd (NYSE-NSRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Nasus Pharma Ltd (NYSE-NSRX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Nasus Pharma Ltd (NYSE-NSRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Nasus Pharma Ltd (NYSE-NSRX) Stock Forecast & Technical Outlook

Review Nasus Pharma Ltd (NYSE-NSRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Nasus Pharma Ltd (NYSE-NSRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Nasus Pharma Ltd (NYSE-NSRX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Nasus Pharma Ltd (NYSE-NSRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Nasus Pharma Ltd (NYSE-NSRX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Nasus Pharma Ltd (NYSE-NSRX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Nasus Pharma Ltd (NYSE-NSRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Nasus Pharma Ltd (NYSE-NSRX) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Nasus Pharma Ltd (NYSE-NSRX) Stock FAQ

Quick answers about Nasus Pharma Ltd (NYSE-NSRX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$2.37
Estimated downside 21.7%
Valuation Rating
Overvalued
Estimated downside of 21.7%
Analyst Target
$19.67
Implied upside 549.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Nasus Pharma Ltd (NYSE-NSRX) is $2.37. This implies an estimated downside of 21.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 21.7% versus the current market price.

The available analyst price target for Nasus Pharma Ltd (NYSE-NSRX) is $19.67. The analyst target implies estimated upside of 549.1%.

The current financial health read for Nasus Pharma Ltd (NYSE-NSRX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Nasus Pharma Ltd (NYSE-NSRX) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Nasus Pharma Ltd (NYSE-NSRX) is -6.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Nasus Pharma Ltd is 35.25 M.

The current enterprise value listed for Nasus Pharma Ltd is 31.316 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nasus Pharma Ltd is NYSE-NSRX, and the stock is listed on NYSE.

Nasus Pharma Ltd (NYSE-NSRX) is listed on NYSE.

The current debt-to-total-capital ratio listed for Nasus Pharma Ltd is 0.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nasus Pharma Ltd is 41.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NYSE View more

Eli Lilly and Company (LLY) Eli Lilly and Company (LLY)
Johnson & Johnson (JNJ) Johnson & Johnson (JNJ)
Merck & Company Inc (MRK) Merck & Company Inc (MRK)
Novartis AG ADR (NVS) Novartis AG ADR (NVS)
Novo Nordisk A/S (NVO) Novo Nordisk A/S (NVO)
Pfizer Inc (PFE) Pfizer Inc (PFE)
Bristol-Myers Squibb Company (BMY) Bristol-Myers Squibb Company (BMY)
GSK plc DRC (GSK) GSK plc DRC (GSK)
Takeda Pharmaceutical Co Ltd ADR (TAK) Takeda Pharmaceutical Co Ltd ADR (TAK)
HALEON PLC ADR (HLN) HALEON PLC ADR (HLN)
Teva Pharma Industries Ltd ADR (TEVA) Teva Pharma Industries Ltd ADR (TEVA)
Zoetis Inc (ZTS) Zoetis Inc (ZTS)
Elanco Animal Health (ELAN) Elanco Animal Health (ELAN)
Dr. Reddy’s Laboratories Ltd ADR (RDY) Dr. Reddy’s Laboratories Ltd ADR (RDY)
Veradermics Inc (MANE) Veradermics Inc (MANE)
Organon & Co (OGN) Organon & Co (OGN)
Prestige Consumer Healthcare Inc (PBH) Prestige Consumer Healthcare Inc (PBH)
Nuvation Bio Inc (NUVB) Nuvation Bio Inc (NUVB)
Bausch Health Companies Inc (BHC) Bausch Health Companies Inc (BHC)
Perrigo Company PLC (PRGO) Perrigo Company PLC (PRGO)
Alto Neuroscience Inc (ANRO) Alto Neuroscience Inc (ANRO)
Rafael Holdings Inc Class B (RFL) Rafael Holdings Inc Class B (RFL)
Impact Biomedical Inc (IBO) Impact Biomedical Inc (IBO)
China Pharma Holdings Inc (CPHI) China Pharma Holdings Inc (CPHI)